A chronic, multifactorial, inflammatory skin condition with extensive underlying mechanisms,
the current therapeutic options for acne vulgaris (AV) are governed by strict regimes and
acute side effects. Özlü and Karadağ focus on the role of the innate immune response in AV
aetiopathogenesis, namely that of toll-like receptor activation and subsequent antimicrobial
peptide release. The authors allude to the possibility of applying their findings for novel
drug development, a promising advance in the field of dermatology for the improvement of
quality of life in affected patients.
Emin Özlü,1 *Ayşe Serap Karadağ2
1. Department of Dermatology, Kayseri Training and Research Hospital, Kayseri, Turkey
2. Department of Dermatology, School of Medicine, Istanbul Medeniyet University, Istanbul, Turkey
*Correspondence to firstname.lastname@example.org
Disclosure: The authors have declared no conflicts of interest.
Received: 01.07.16 Accepted: 12.10.16
Citation: EMJ Dermatol. 2016;4:76-82.
Acne vulgaris (AV) is a chronic inflammatory disease of the pilosebaceous unit. AV has a multifactorial pathogenesis with specific roles played by the sebaceous glands, abnormal follicular hyperkeratinisation, inflammation, Propionibacterium acnes, hormonal factors, immune mediators, and genetic and environmental factors. Significant improvements have been made to elucidate acne pathogenesis, through developments in molecular biology, immunology, and genetic techniques. Toll-like receptors and antimicrobial peptides play significant roles in the host defense system against different pathogenic micro-organisms on the skin and these molecules induce several immunological responses. It is well known that toll-like receptors and antimicrobial peptides play important roles in AV pathogenesis and further understanding of these will contribute to improvements in treatment.